Virtify, Inc. and IMS Health (NYSE: RX) have partnered to jointly deliver Enterprise Content Compliance (ECC) solutions to the European marketplace.
The partnership will combine Virtify’s Virtx ECC Software Suite with comprehensive IMS services to help client companies manage regulated content and compliance issues throughout the product continuum. Virtify’s integrated software suite is an XML-based platform for structured content management, global labeling, submissions, and clinical trial disclosure that enables life sciences customers to reduce costs, mitigate risk and accelerate time to peak sales. Together, IMS and Virtify are uniquely qualified to service the needs of life sciences companies, through a combination of industry expertise, solutions, and comprehensive services. With over 50 years of dedicated life sciences experience, the partnership offers:
• Integrated business process consulting, technology, and services delivery
• Scalable structured content management
• Compliant labeling, submissions, and clinical trial disclosure solutions
• 3,000 customers worldwide
• Global presence
According to industry analyst firm IDC, the cost of bringing a new drug to market ranges from $800 million to $1.2 billion with close to a quarter of these costs coming from the content requirements associated with working in a regulatory compliant environment. The Virtx ECC Software Suite is engineered to meet these specific needs in the highly regulated pharmaceutical, biotechnology, medical device, animal health and food sciences industries.
The integrated Virtx Software Suite provides a secure, collaborative online environment for managing and reusing regulated content. It enables customers to manage the processes of submissions, document creation and review, global labeling, clinical trial disclosure and other regulatory management activities from a single platform.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.